Anavex Life Sciences Corp (AVXL)

[falconer66a]

My Take.

Bourbon’s points, from the shareholders’ meeting:

1. Long term users are showing sustained improvement and or stability.

Well, does Anavex 2-73 work, or not? Somebody, quick, find a study showing similar results with any of the four existing Standard of Care Alzheimer’s drugs.

Letting this assertion stand could convince some to think the Anavex story is true. There’s just gotta be a drug keeping early or mid stage Alzheimer’s victims mentally alert after three years of treatment.

2. Specific markers have been found that determine whether or not a patient will respond to Anavex 2-73.

How can this be true? I’ve just read so many postings telling, so authoritatively, that Anavex 2-73 simply doesn’t work; that the Australians continuing to take their doses 3 years after the trial ended down there are just placebo-deceived. No possible biomarkers for Anavex efficacy. Read it here.

3. Stephen Toutain is a key hire...to help the Rett girls.

Very well. Of no contention.

4. ...our tests will be designed to enable AVXL to apply for accelerated approval.

Really? Pretty fine, then. But experts here say such is not possible; that accelerated approvals are not tolerated. Who would know?

5. They have precise data on the optimal effective dose.

How could they? How many experts here have posted that optimal dosing simply didn’t, can’t, or won’t be achieved? The experts here know better, don’t they? Without precise dosings, none of the upcoming clinical trials will have validity. Dosings of neurotropic drugs are tricky, aren’t they?

6. Cash is $28 million, enough to fund the company for 2 years.

I better sell my few shares, then. How can a pharmaceutical survive on only $28 million in the bank?

7. FDA relations are very good.

Na, FDA old-timers are stuck in the last century; gotta have long, old textbook double-blind clinical trials. Have read here how none of the upcoming trials could really work to prove Anavex efficacy, if they can even be put together and conducted.

Anavex talks with FDA, and they talk back? What a thing.



Who am I gonna believe? I think I’ll keep my small AVXL position. No way for me to have attended the shareholder meeting. Thanks, Bourbon, for being there and telling what you heard. More significant than anything I’ve read here for some time.